Profile data is unavailable for this security.
About the company
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
- Revenue in USD (TTM)24.52m
- Net income in USD-72.12m
- Incorporated2015
- Employees112.00
- LocationFoghorn Therapeutics Inc500 Technology Square, Suite 700CAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 586-3100
- Fax+1 (302) 655-5049
- Websitehttps://foghorntx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 296.72m | 60.00 | -- | -- | -- | 58.71 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| OpGen Inc | 9.00m | 6.70m | 304.38m | 1.00 | 45.54 | 29.73 | 44.17 | 33.82 | 0.6585 | 0.6585 | 0.8894 | 1.01 | 0.994 | -- | 4.42 | 9,000,000.00 | 75.58 | -74.71 | 81.77 | -111.02 | 100.00 | 30.79 | 76.04 | -602.64 | -- | -- | 0.00 | -- | 52.01 | 8.23 | 134.76 | -- | -- | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 306.48m | 275.00 | -- | 0.0334 | -- | 1.35 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -40.35m | 307.61m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Prenetics Global Ltd | 66.32m | -40.67m | 309.90m | 285.00 | -- | 1.54 | -- | 4.67 | -3.10 | -3.54 | 5.01 | 14.26 | 0.3068 | 4.83 | 17.70 | 232,698.60 | -20.40 | -60.40 | -25.34 | -81.53 | 48.01 | 40.86 | -66.49 | -385.99 | 2.51 | -3.83 | 0.0129 | -- | 40.83 | 27.10 | 14.76 | -- | 23.29 | -- |
| Candel Therapeutics Inc | 0.00 | -22.76m | 311.82m | 38.00 | -- | 3.89 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -43.19m | 317.66m | 9.00 | -- | 6.45 | -- | -- | -0.7217 | -0.7217 | 0.00 | 0.8185 | 0.00 | -- | -- | 0.00 | -44.27 | -34.06 | -57.79 | -38.07 | -- | -- | -- | -- | -- | -- | 0.2359 | -- | -- | -- | -48.77 | -- | -- | -- |
| Immuneering Corp | 0.00 | -62.50m | 318.33m | 54.00 | -- | 1.37 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 325.08m | 112.00 | -- | -- | -- | 13.26 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 336.12m | 28.00 | -- | 1.90 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 336.73m | 56.00 | -- | 1.07 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 345.62m | 64.00 | -- | 2.88 | -- | 21.96 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 350.92m | 123.00 | -- | 44.30 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 353.71m | 106.00 | -- | 2.24 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 353.89m | 299.00 | -- | 1.13 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
| Benitec Biopharma Inc | 0.00 | -41.82m | 355.57m | 19.00 | -- | 2.91 | -- | -- | -1.18 | -1.18 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -50.76 | -79.73 | -52.87 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
Data as of Feb 13 2026. Currency figures normalised to Foghorn Therapeutics Inc's reporting currency: US Dollar USD
33.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 5.47m | 9.35% |
| BVF Partners LPas of 30 Sep 2025 | 5.30m | 9.05% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 2025 | 2.46m | 4.20% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.13m | 3.64% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.68m | 2.86% |
| Geode Capital Management LLCas of 31 Dec 2025 | 795.04k | 1.36% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 618.67k | 1.06% |
| Point72 Asset Management LPas of 30 Sep 2025 | 371.03k | 0.63% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 297.74k | 0.51% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 284.30k | 0.49% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
